Security Type: Depository Receipt
Bid 86.63
Bid Size 8
Ask 86.65
Ask Size 1
Open 86.45
Day High 86.73
Day Low 86.40
Previous Close 85.95
52-Week High 106.84
52-Week Low 85.78
Price Performance (Last 52 Weeks)-9.56%
Held by ETPs
Yes (16)
Volume 409,960
90-Day Average Volume 1,801,083
Primary Exchange NYSE
Index Not In
S&P 500®

Detailed Quote

Note: You can save only one view at the time. Saving this view will overwrite your previously saved view.

Please use the Advanced Chart if you want to have more than one view.

Save View
Your view has been saved
Your view hasn't been saved
TODAY 2D 5D 10D 1M 3M 6M YTD 1Y 3Y 5Y 10Y
Text Note
Chart Settings

Please note you can display only one indicator at a time in this view. Please use Advanced Chart if you want to display more than one.


Please note you can display only one indicator at a time in this view. Please use Advanced Chart if you want to display more than one.

Don't show again

News & Events

Log in for more news
  • Show article details.

    Prescription Skin Drugs Explode in Costs, Study Shows

    DJ Business News – 11/25/2015

    Retail prices of 19 brand-name prescription drugs for dermatologic conditions ranging from acne to cancer increased fivefold on average between 2009 and 2015, according to a study that adds new fuel to the burgeoning debate over the cost of medicines. In the most dramatic case, a 2- ounce tube of gel called, Targretin marketed by Valeant Pharmaceuticals International Inc. (VRX) for a type of skin cancer, jumped to $30,320 this year from $15,708 last year and $1,687 in 2009, the report...

  • Show article details.

    Novartis gets FDA approval for skin cancer drug combination

    Reuters – 11/20/2015

    Novartis AG (NVS) said on Friday it received the U.S. Food and Drug Administration's regular approval for a drug combination to treat an aggressive form of skin cancer. The FDA approved Tafinlar and Mekinist for treatment of metastatic melanoma based on two years overall survival in patients, the company said.

  • Show article details.

    Novartis Finalizes Settlement With Justice Department

    DJ Business News – 11/20/2015

    Novartis AG (NVS) has finalized a settlement with the U.S. Justice Department concerning rebates it paid to specialty pharmacies and has agreed to certain provisions on its interactions with the pharmacies. In October, the Basel, Switzerland-based drug company said it agreed to pay $390 million as part of a settlement regarding claims that it paid kickbacks in the form of rebates to boost prescriptions for Novartis (NVS) drugs.

  • Show article details.

    Novartis to pay $390 mln in U.S. settlement over pharmacy kickbacks

    Reuters – 11/20/2015

    Novartis Pharmaceuticals Corp will pay $390 million to resolve U.S. charges alleging it paid specialty pharmacies illegal kickbacks in exchange for inducing patients to refill certain medications, according to a court filing on Friday.

  • Show article details.

    Bumper haul of expensive new drugs heads to U.S. and Europe

    Reuters – 11/20/2015

    * Speedy drug approvals bolster industry's product line-up. * U.S. regulator clears 37 new drugs, ahead of year-ago level. * High cost of many new medicines prompts protests. * Drug research focused on medicines for rich countries. By Ben Hirschler.


  • Jan

    NVS to announce Q4 earnings Before Market (Unconfirmed)

  • Feb

    Shareholders Meeting

More News & Events

Company Profile

Log in for more information

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology…

View more

Sector (GICS®)

Health Care

Industry (GICS®)


Environmental, Social & Governance Summary (ESG)

  Secure. Log in required.

ESG ratings enable you to leverage independent ESG research to evaluate how companies are managing ESG risks and addressing ESG opportunities. Learn more

Accounting & Governance Risk Score (AGR®)

  Secure. Log in required.

The GMI Accounting and Governance Risk (AGR®) Score & Rating is widely recognized as an indicator of the confidence level surrounding a company's management and reported financials. Learn more

About Environmental, Social & Governance Summary (ESG)

GMI ESG Ratings

Environmental, Social, and Governance (ESG) Flags: GMI Ratings publishes Environmental, Social and Governance (ESG) ratings on over 6,000 companies worldwide. These ratings provide an independent assessment of the sustainable investment value of public companies. The ESG Ratings model is based on a carefully crafted and applied list of KeyMetrics® that result in an overall ESG concern level as expressed by Red (High Concern), Yellow (Average Concern), and Green (Low Concern) flags. Unlike traditional ESG risk models, GMI's rating methodology is designed to identify risks most likely to affect equity valuations. Specifically, these ratings reflect actual corporate behaviors rather than policies or affirmations of intent to adhere to best ESG practices. Further, unlike other models with evenly weighted metrics, we assign context-sensitive relative weightings to our key metrics, based on market, regional, ownership or sector differences. Individual company scores are then assigned as a percentile rank, ranging from 1 (worst ranked) to 100 (best) on the basis of these KeyMetrics® and then converted to the Red, Yellow or Green flag designation.

Company Reports: In addition to a company's overall risk rating, ESG reports also include an industry rating based on a comparison between the company's risk levels in each ESG component area relative to its industry peers. Further, the ESG analysis serves as a summary of behavioral events that contributed to the company's overall risk level.

More About GMI

GMI Accounting and Governance Risk (AGR) Score & Rating

The GMI Accounting and Governance Risk (AGR) Score & Rating is widely recognized as an indicator of the confidence level surrounding a company's management and reported financials.

Scores range from 0 to 100, and correspond to a risk classification for each company ranging from "Very Aggressive" to "Conservative." The AGR Score is a percentile ranking among the approximately 8,000 companies rated by GMI. Through continued back-testing, GMI has demonstrated a strong correlation between its quarterly AGR Score and the likelihood of adverse events, including securities class action litigation, financial restatements, regulatory enforcement actions, and stock price declines. Thus, a company's AGR Score can help investors looking to manage risk or enhance investment performance. GMI forensically analyzes the financial reporting and governance practices of over 8,000 North American-based publicly traded companies.

About GMI

GMI is an independent risk research firm which provides a statistically modeled assessment of corporate integrity. Founded in 2002 in direct response to the growing number of scandals, lawsuits and investor losses resulting from fraudulent corporate behavior, the firm identifies potential high-risk company accounting and governance activity, which in turn has been historically correlated to stock price declines, securities class-action litigation, and material financial restatements. The product of GMI's analysis is a unique risk measure - the AGR Score which can be used by investors as a way to more effectively manage corporate risk.

More About GMI

Full Time Employees: 133,413

Executives  Secure. Log in required.

Lichtstrasse 35
Basel,  4056

1-41 61 324 11 11

Analyst Opinions

The Equity Summary Score is an accuracy-weighted sentiment derived from the ratings of independent research providers on It uses the past relative accuracy of the providers in determining the emphasis placed on any individual opinion. Learn More....

Log in to view the Equity Summary Score for NVS

Research Reports

Company Research Highlights® Report (PDF) Requires Login.

This generated report* compiles independent, third-party information highlighting key fundamental and technical data, analyst opinions, stock price movement, earnings data, and industry comparisons. Available only to Fidelity customers.

S&P Capital IQ ® Company Report Requires Login.

This generated report* has historical data on financials with interactive charts, technical indicators, and five-year peer comparison trend charts.

*Generated reports are built dynamically when you select them. Reports may not be available for some symbols. Select the link to check availability for this symbol.

NVS Industry Comparison:

NVSIndustry AveragePercentile
in Industry
Market Capitalization$203.65B$32.95B100th
Total Return (1 Year Annualized)
Beta (1 Year Annualized)0.700.7626th
Current Consensus EPS Estimate$1.26----
EPS Growth
(TTM vs. Prior TTM)
Dividend Yield (Annualized)
Total Revenue (TTM)
Revenue Growth
(TTM vs Prior TTM)
Shares Outstanding2,369,426,0002,483,585,79296th
Shares Short*
Institutional Ownership9.73%43.81%26th

* Short Interest data provided by NASDAQ, NYSE, or AMEX and is updated periodically and on a bi-monthly basis (depending on the listing exchange).

† The Equity Summary Score provided by StarMine is current as of the date specified. There may be differences between the Equity Summary Score analyst count and the number of underlying analysts listed. Due to the timing in receiving ratings changes into the Equity Summary Score model, the Equity Summary Score analyst count may lag the ratings count displayed by one or more days. There may also be analyst count variations for symbols with multiple share classes and ADRs. More details on Equity Summary Score calculation are included in the Understanding and Using the Equity Summary Score Methodology (PDF).

As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.

Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.